Armata Pharmaceuticals, Inc. (ARMP) stock
ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.66−0.33 (-11.04%)
Close on Nov 17, 2026Market cap $98.90MP/E –Yield –
Armata Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Armata Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.42M. For fiscal 2025 it was -$25.76M. The highest annual figure on record is -$6.29M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.76M | – |
| FY2024 | Dec 31, 2024 | -$37.55M | – |
| FY2023 | Dec 31, 2023 | -$47.42M | – |
| FY2022 | Dec 31, 2022 | -$32.48M | – |
| FY2021 | Dec 31, 2021 | -$23.58M | – |
| FY2020 | Dec 31, 2020 | -$18.27M | – |
| FY2019 | Dec 31, 2019 | -$15.58M | – |
| FY2018 | Dec 31, 2018 | -$10.63M | – |
| FY2017 | Dec 31, 2017 | -$9.19M | – |
| FY2016 | Dec 31, 2016 | -$10.61M | – |
| FY2015 | Dec 31, 2015 | -$9.78M | – |
| FY2014 | Dec 31, 2014 | -$12.57M | – |
| FY2013 | Dec 31, 2013 | -$6.29M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.67M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.58M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.33M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.83M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.46M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.20M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.54M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$593.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.50M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.13M | – |
See a number that looks wrong?